Cancer Immunotherapy Study Gets Major Correction Three Years Later

A 2020 study on boosting cancer-fighting immune cells using nanoparticles has been formally corrected by its authors. While the full nature of the correction remains undisclosed, the delayed corrigendum raises questions about the robustness of findings in emerging immunotherapy research—relevant for biotech firms and healthcare investors evaluating pipeline candidates.

Originaltitel: Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240].